Literature DB >> 324510

Asthmatic pulmonary eosinophilia: a review of 65 cases.

W G Middleton, I C Paterson, I W Grant, A C Douglas.   

Abstract

In a series of 65 patients with asthma with pulmonary eosinophilia 54 were adequately investigated for allergic aspergillosis and this was present in 32 (59%). Asthma with pulmonary eosinophilia was found to carry a relatively poor prognosis in terms of permanent symptoms, impairment of pulmonary function and residual radiographic abnormality. The prognosis was least favourable when allergic aspergillosis was associated with long-standing asthma. On the other hand there was a group of patients with asthma with pulmonary eosinophilia who had relatively little permanent disability. These were mainly women with asthma of recent onset, and in these evidence of allergy to Aspergillus fumigatus was less apparent. Those patients who received long-term daily corticosteroid therapy were less likely to develop further radiographic opacities than those given intermittent corticosteroid therapy. To prevent recurrent pulmonary infiltrates it is probably necessary to give prednisolone in a daily dosage of at least 10 mg for an indefinite period.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324510     DOI: 10.1016/0007-0971(77)90092-4

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  4 in total

1.  Corticosteroid treatment and prognosis in pulmonary eosinophilia.

Authors:  S Capewell; B J Chapman; F Alexander; A P Greening; G K Crompton
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

2.  The spectrum of pulmonary aspergillosis.

Authors:  G McCarthy; M X FitzGerald; P Keelan
Journal:  Ir J Med Sci       Date:  1988-10       Impact factor: 1.568

3.  Pulmonary eosinophilia with and without allergic bronchopulmonary aspergillosis.

Authors:  B J Chapman; S Capewell; R Gibson; A P Greening; G K Crompton
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

Review 4.  Allergic bronchopulmonary aspergillosis: a review.

Authors:  A Wardlaw; D M Geddes
Journal:  J R Soc Med       Date:  1992-12       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.